MedTrace Logo

Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics

NCT03094897 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-04-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether 18F-Al-NOTA-MATBBN is safety and effective for cancer diagnosis.

Conditions

  • Breast Neoplasms
  • Prostatic Neoplasms

Interventions

DRUG

18F-Al-NOTA-MATBBN PET/CT

18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.

DEVICE

PET/CT

Imaging with 18F-Al-NOTA-MATBBN PET/CT.

Sponsors & Collaborators

  • Wuxi No. 4 People's Hospital

    lead OTHER

Principal Investigators

  • chunjing Yu, PhD · Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital)

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-20
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03094897 on ClinicalTrials.gov